Lymphoma PDX Models

Identifying robust preclinical models for lymphoma is essential for the development of new therapies targeting this disease. Patient-derived xenograft (PDX) models provide a predictive preclinical model with true representation of the human heterogeneity providing an accurate approach to predicting an agent’s efficacy prior to entering the clinic. The Crown Bioscience lymphoma PDX collection consists of many models, including both primary and metastatic models. More

PDX offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials. Crown Bioscience’s HuPrime® PDX models are well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.
MODEL NUMBERCANCER SUBTYPE # per page
LY3786 NACLICK TO VIEW
LY6696 NACLICK TO VIEW
LY6701 DLBCL, GCBCLICK TO VIEW
LY6931 ALCL, anaplastic large cell lymphomaCLICK TO VIEW
LY6933 NHL (DLBCL, ABC/GCB)CLICK TO VIEW
LY6934 NHL (DLBCL, ABC/GCB)CLICK TO VIEW
LY6938 LymphomaCLICK TO VIEW

Create HuBase Account to View All Model Data

Already Registered? Login